Prostate Cancer

A 10-year analysis of 3477 patients found low prostate cancer–specific mortality with focal high-intensity focused ultrasound or cryotherapy for nonmetastatic disease.

Patients with clinically higher-risk disease but favorable GPS results had higher 6-year EFS rates across treatment arms vs those at a lower clinical risk.

Findings from the phase 3 CAPItello-281 trial supported the regulatory decision for capivasertib among this PTEN-deficient HSPC group.

The clearance enables the developers to include China-based centers in an ongoing phase 1a/1b trial evaluating the agent in late-stage solid tumors.

NCCN-indicated germline and somatic testing performance was inconsistent, although rates have been increasing due to concurrent quality improvement efforts.

Among patients treated in the PSMAtrack analysis, all had residual PSMA-avid disease following 6 months of systemic therapy for metastatic HSPC.

Patients with positive images may benefit from additional therapy not directed at the androgen receptor; however, prospective validation is required.

Patients were 9 times more likely to have little to no cancer remaining after their procedure with the apalutamide doublet compared with placebo plus ADT.

Enrollment for the WATER IV study evaluating aquablation vs radical prostatectomy has concluded, with primary end point results planned by spring 2027.

The ArteraAI Prostate Test is now available to predict mortality risk and guide treatment for metastatic hormone-sensitive prostate cancer.

PSA score at 24 weeks was the strongest predictor of survival, with a PSA concentration of 0.2 ng/mL or less predicting favorable outcomes in this group.

New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.

Based on the clinical efficacy, ODAC members collectively voted to support the sNDA for capivasertib in this PTEN-deficient HSPC population.

Recently, conservative management has grown in popularity, especially among older patients and those with higher neighborhood-level socioeconomic status.

Most treatment-related adverse effects were grades 1 or 2, and no grade 4 adverse effects or treatment-related deaths were observed with Lu-PSMA-617.

Mina Fam, MD, explored the integration of multiparametric MRI and genomics in focal HIFU selection and compared its AE profile to radical intervention.

Investigators of a prospective validation study highlighted the potential of a urine-based assay to reduce surgical biopsies deemed unnecessary.

Management strategies for oxybutynin-induced xerostomia include hydration, sugar-free gum, and humidification.

The project will be focused on increasing awareness and early detection of the disease and generate high-quality data to inform improvement of care.

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.

The phase 3 TALAPRO-3 study met its primary end point, showing a clinically meaningful reduction in the risk of progression or death in HRR-mutant HSPC.

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.

Emergent phase 1 LuPARP study data suggest that metastatic castration-resistant prostate cancer could be treated with PARP inhibition and radionuclides.

Twenty patients with low- to intermediate-risk localized prostate cancer underwent successful implantation with the antiandrogen-eluting implants.